Letters Polypharmacy

Problems of polypharmacy

BMJ 2013; 347 doi: http://dx.doi.org/10.1136/bmj.f7500 (Published 23 December 2013) Cite this as: BMJ 2013;347:f7500
  1. Andrew Herxheimer, emeritus fellow1,
  2. Patricia McGettigan, clinical pharmacologist2
  1. 1UK Cochrane Centre, Oxford, UK
  2. 2William Harvey Research Institute, Barts and London School of Medicine and Dentistry, London EC1M 6BQ, UK
  1. a.herxheimer{at}ntlworld.com

The King’s Fund report discussed by Wise covers much ground, but its focus is blurred and it misses some core points.1 2 It would take years to implement the sensible changes proposed in managing multimorbidity and in prescribing in care homes. But what do the authors think should be done now?

They strangely omit the role of the patient. Patients (and …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe